A recent study in women with HER2-negative/estrogen receptor-positive early breast cancer investigated a de-escalated chemotherapy approach with the main aim of reducing its gonadotoxicity by removing the cyclophosphamide component without compromising its prognosis. Here, ERBB2 is linked to breast cancer.